Boehringer's Empagliflozin Heads To Advisory Cmte. With Questions On Treatment Effect

 
• By Michael Cipriano

Boehringer wants supplemental empagliflozin claim as insulin adjunct to improve glycemic control in type 1 diabetes, but US FDA questions the size of the clinical benefit and the magnitude of a diabetic ketoacidosis risk.

Diabetes
A US FDA advisory committee will assess Boehringer Ingelheim's empagliflozin for a type 1 diabetes indication.

More from US FDA Performance Tracker

More from Regulatory Trackers